ClinicalTrials.gg
CompletedNCT06842745TMSUpdated Nov 20, 2026

Transcranial Magnetic Stimulation + Language Therapy to Treat Mild Aphasia

A Phase 2 interventional study of Transcranial Magnetic Stimulation (TMS) and Speech-Language Therapy (SLT) in Aphasia, Stroke and Aphasia Following Cerebral Infarction, sponsored by University of Pennsylvania. Completed at 1 site in United States. Open to participants aged 40 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-11-20.

Sponsored by University of Pennsylvania · Phase 2, Interventional, and Treatment

How we know

Updated Nov 20, 2026Now CompletedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
32
Allocation
Randomized
Ages
40 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 175 studies in Aphasia with a site in United States — 49 open to participants now, 59 under way, 1 of them phase 3. Aphasia · United States.

Enrollment
75th of 158
32 · median 30
Started
2025
with 11 others
Phase 2
15 of 175
6 open now
Registered
155th of 175
by date
Lead sponsor
7 of 175
University of Pennsylvania

Among the 175 studies in Aphasia with a site in United States, this one is the 75th largest by enrollment of the 158 interventional ones that give a count, is one of 12 that started in 2025, is one of 15 in phase 2, and was the 155th registered.

Aphasia

338 studies on the registry are indexed under Aphasia; 93 are open to participants now.

Browse Aphasia studies →

Open to participants now

49 of the 175 studies in Aphasia with a site in United States are open now. Recruiting first, the newest first:

44 more — sign in →

All 49 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 66 Aphasia studies recruiting now, 30 (45%) set no upper age limit and 11 (17%) stop at 75 or younger; 1 takes children under 18; 16 take healthy volunteers.

This study: 40 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 175 studies in Aphasia with a site in United States, or all of them as a file.
02

Study summary

The goal of this clinical trial is to determine if Transcranial Magnetic Stimulation (TMS) combined with Speech-Language Therapy (SLT) is an effective treatment for mild aphasia in persons with chronic stroke.

The main questions this study aims to answer are:

  1. Can TMS combined with SLT improve conversational speech and comprehension?
  2. Can we identify specific behavioral and biological characteristics that would benefit most from the TMS and SLT treatment?

Researchers will compare real TMS to sham (fake) TMS to see whether TMS can treat post-stroke mild aphasia.

Participants will:

  • Complete a screening and medical intake to determine eligibility
  • Undergo a MRI
  • Participate in 10 consecutive sessions (Monday-Friday) of TMS and SLT treatment
  • Complete follow-up assessments 2 and 4 months after treatment
Read the detailed description

Aphasia is an acquired disorder of language that occurs in approximately 30% of individuals with stroke and impacts approximately 1 million Americans (see NINDS.NIH.gov). Current treatments for aphasia are only modestly beneficial, so there is a clear need for more efficacious therapy.

Previous research has demonstrated that TMS improves language performance in persons with aphasia and the benefit has been shown to be sustained. All studies of which we are aware, however, have included participants with moderate/severe aphasia. The issue of mild aphasia has received little attention to date but as there is an increasing recognition that even very mild language deficits have important negative consequences for employment and social well-being. This study will aim to treat mild aphasia with TMS and SLT emphasizing conversations speech.

One limitation of TMS has been variability in response; TMS has shown good within-subject reliability but more substantial variability between subjects. In recognition of these issues, "electrical field" (e-field) models have been developed to account for these individual differences in anatomy. We will the utilize e-field models in conjunction with an individually determined resting motor threshold to generate a personalized treatment regimen that is likely to ensure that all subjects receive the same TMS intensity relative to their individual motor threshold and greatly reduces the possibility of under- or over-dosing with respect to TMS intensity. We will employ continuous theta-burst stimulation, 600 brief electrical pulses delivered in 40 seconds, over the right front part of the brain (pars triangularis).

Participants who are enrolled can expect to undergo a battery of tests to define their language function as well as a research MRI scan that will be used to guide TMS therapy and to assess the size and location of the stroke and its impact on brain pathways. After baseline testing, subjects will undergo treatment using TMS (or sham) + SLT for 10 sessions (Monday-Friday) over the course of 2 consecutives week. Follow-up assessment of language functioning will be assessed immediately, 2 months and 4 months after treatment.

Participants will be compensated for their time and travel.

03

Conditions studied

  • Aphasia
  • Stroke
  • Aphasia Following Cerebral Infarction
  • Aphasia, Acquired

Browse trials for

Keywords

  • aphasia
  • stroke
  • non-invasive brain stimulation
  • Transcranial Magnetic Stimulation
04

Who can participate

Ages eligible
40 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Left Hemisphere stroke
  • Stroke occurred more than 6 months ago
  • Mild Aphasia (WAB AQ score > 85)
  • Proficient in English

Exclusion criteria

Exclusion Criteria:

  • Ongoing substance or alcohol abuse
  • Other neurological disorders, beside stroke (i.e. dementia, traumatic brain injury, multiple sclerosis)
  • Active psychiatric disorders (i.e. bipolar disorder, schizophrenia)
  • Pacemaker or cardiac defibrillator
  • Diagnosis of tinnitus
  • Epilepsy, or seizure in the past 6 months
05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
32 participants (actual)

Study arms

  • Experimental
    Real TMS

    Some of our participants will be randomized to the real treatment arm where they will receive 10 sessions of real TMS paired with speech-language therapy.

    Device: Transcranial Magnetic Stimulation (TMS) · Behavioral: Speech-Language Therapy (SLT)

  • Sham comparator
    Fake TMS

    Some of our participants will be randomized to the sham treatment arm where they will receive 10 sessions of fake TMS paired with speech-language therapy.

    Behavioral: Speech-Language Therapy (SLT)

Interventions

  • DeviceTranscranial Magnetic Stimulation (TMS)

    TMS, is a form of non-invasive brain stimulation, that uses magnetic pulses to stimulate specific areas of the brain. In this study we will utilize theta-burst stimulation which uses a higher frequency pulse of 50 Hz delivered for 40 seconds for a total of 600 pulses.

  • BehavioralSpeech-Language Therapy (SLT)

    Our SLT protocol draws from two theories and evidence-based cognitive-linguistic frameworks: (1) conversational alignment, which engages priming of lexical and syntactic structures through dialogue and conversation and (2) increased tolerance of memory load in the context of sentence repetition and dialogue tasks. Administration of these tasks will abide by principles of constraint-induced language therapy, i.e., intense treatment schedule and verbal responding only. All participants will receive SLT.

06

What researchers measure

Primary outcomes

  1. Sentence Processing

    Change in performance on the Temple Assessment of Language and Short-term Memory in Aphasia (TALSA) sentence processing composite score.

    Time frame: From baseline to 4 months post-intervention

Secondary outcomes

  1. Semantic and Phonological Processing

    Change in performance on the TALSA composite semantic processing score and phonological processing score.

    Time frame: From baseline to 4 months post-intervention

  2. Elicited Speech

    Change in performance on the Nicholas \& Brookshire picture description and Story Retell scores.

    Time frame: From baseline to 4 months post-intervention

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No — No, the study team does not plan to share participating data at this time.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Feb 2025 to primary completion in Oct 2026, 20 months.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 20, 2026: primary completion Aug 2026 → Oct 2026 and completion Aug 2026 → Oct 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Feb 18, 2025
First posted
Feb 24, 2025
StartActual
Feb 11, 2025
Primary completionActual
Oct 31, 2026was Aug 2026
CompletionActual
Oct 31, 2026was Aug 2026
Last update
Nov 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Completed
changed Nov 20, 2026
Primary completion
Aug 31, 2026→Oct 31, 2026 (actual)
Nov 20, 2026
Study completion
Aug 31, 2026→Oct 31, 2026 (actual)
Nov 20, 2026
Enrollment
24 (estimated)→32 (actual)
Nov 20, 2026
Show all 1 update
  1. Nov 20, 2026
    Recruiting→Completed
    Primary completion Aug 31, 2026→Oct 31, 2026 (now actual)
    Study completion Aug 31, 2026→Oct 31, 2026 (now actual)
    Enrollment 24 (estimated)→32 (actual)
    + 3 other changes: verification date, contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06842745
Responsible party
Sponsor
First posted
Feb 24, 2025
Start date
Feb 11, 2025
Primary completion
Oct 31, 2026
Completion
Oct 31, 2026
Last update
Nov 20, 2026

Study contacts

H. Branch Coslett, MD
principal investigator · University of Pennsylvania

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion